ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

petrelintide

Also written as “Petrelintide” and “ZP8396”.

Its studies are mostly in Obesity · Overweight · Renal Insufficiency, led by 2 companies.

Drug pagePetrelintide: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 25, 202411 company-led studies, 5 open or runningCo-development: Zealand Pharma and Roche, Mar 2025Next primary completion: Apr 12, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zealand Pharma71 open or runningphase 2since Oct 25, 2024Oct 14, 2021Apr 12, 2027phase 1 · NCT07682818
Hoffmann-La Rocheits history only44 open or runningphase 3since Sep 11, 2026May 11, 2026Nov 12, 2027phase 2 · NCT07589686
  • Named in Hoffmann-La Roche’s own pipeline as RG6849 petrelintide (Zealand), phase 3, as of Oct 22, 2026 (source).

Also a collaborator on its studies: Parexel, ICON Clinical Research and ICON.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Zealand Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 14, 2021First study: phase 1 study in OverweightFirst studyNCT05096598 · 64 enrolled · Germany
  2. Oct 28, 2022Phase 1 study in OverweightNCT05613387 · 68 enrolled · Germany
  3. Aug 6, 2023Named petrelintideINNProposed as its International Nonproprietary Name in WHO's List 129 · before, ZP8396
  4. Oct 25, 2024Phase 2 study in ObesityNCT06662539 · 493 enrolled · United States, Poland, Romania
  5. Mar 12, 2025Roche develops it with Zealand PharmaCo-developmentTogether in the US and Europe; Roche alone elsewhere · announced · Roche
  6. Apr 11, 2025Phase 2 study in OverweightNCT06926842 · 221 enrolled · United States
  7. Jul 10, 2025Phase 1 study in Renal InsufficiencyNCT07076030 · 39 enrolled · Germany
  8. Dec 11, 2025Phase 1 study in ObesityNCT07338214 · 48 enrolled · Germany
  9. Jun 26, 2026Phase 1 study in Impaired Hepatic FunctionNCT07682818 · 36 planned · Poland, Slovakia

Ahead

  1. Apr 12, 2027Primary completion: phase 1 study in Impaired Hepatic FunctionNCT07682818

TargetBeta

CALCR →read by rule
“Petrelintide is a long-acting amylin analog in development for weight management.”study text, by rule · the study

Other programs on CALCR

ProgramCompanyFurthest phaseStudies
cagrilintideNovo Nordiskphase 350
zenagamtideNovo Nordiskphase 336
eloralintideEli Lillyphase 326
ABBV-295AbbViephase 25
PF-08653945Pfizerphase 22
GUB014295AbbViephase 11
CagriSema ANovo Nordiskphase 11

Studies

All 7 Zealand Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07682818Impaired Hepatic Function · Poland, Slovakia1RecruitingApr 12, 202736
NCT07338214Obesity · Germany1CompletedMar 31, 202648
NCT07076030Renal Insufficiency · Germany1CompletedNov 25, 202539
NCT06926842Overweight · United States2CompletedAug 13, 2026221
NCT06662539Obesity · United States, Poland, Romania2CompletedSep 30, 2025493
NCT05613387Overweight · Germany1CompletedJun 13, 202468
NCT05096598Overweight · Germany1CompletedJan 12, 202364

How it is read

Names in the registry

  • “Petrelintide”, 9 entries
  • “ZP8396”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.